• Closed recruitment in Phase III AMPLIFY trial for 64Cu-SAR-bisPSMA
• Presented positive results from Co-PSMA head-to-head trial of 64Cu-SAR-bisPSMA vs. 68Ga-PSMA-11
• Signed manufacturing agreements to secure large-scale supply of copper-64 and 64Cu-SAR-bisPSMA

Clarity Pharmaceuticals has made significant progress during and since the quarter ending 31 March 2026. The company remains well-funded with a cash position of $197.8 million, allowing it to continue advancing its products towards commercialization. Key highlights include:- The registrational Phase III AMPLIFY trial for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer has completed recruitment, with a total of 232 participants dosed and imaged.- Results from the Phase II Co-PSMA investigator-initiated trial, comparing 64Cu-SAR-bisPSMA to standard-of-care 68Ga-PSMA-11, were presented at the European Association of Urology Congress 2026. The trial met its primary endpoint, demonstrating that 64Cu-SAR-bisPSMA identified more than twice as many cancer lesions per patient compared to 68Ga-PSMA-11.- The Phase II SECuRE trial for 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer continues to show promising results, with five patients achieving undetectable disease by radiographic assessment following treatment.- Clarity has secured large-scale manufacturing agreements for copper-64 and 64Cu-SAR-bisPSMA to support anticipated commercial launch, including partnerships with Theragenics and Nucleus RadioPharma.- The company has also strengthened its senior leadership team with the appointments of Chris Horvath as Chief Commercial Officer and Juliane Foley as Vice President of Regulatory Affairs.Overall, Clarity is well-positioned to advance its diagnostic and theranostic programs towards regulatory approvals and commercial launch, with a strong financial position, robust supply chain, and experienced leadership team.

Clarity remains well-funded with a cash position of $197.8 million as of 31 March 2026 to support the continued development and commercialization of its products.

Clarity is focused on completing its two registrational Phase III trials for 64Cu-SAR-bisPSMA, AMPLIFY and CLARIFY, to support regulatory filings. The company is also actively progressing the SECuRE trial for 67Cu-SAR-bisPSMA in metastatic castration-resistant prostate cancer and preparing for a registrational Phase III trial for 64Cu-SARTATE in neuroendocrine tumors.